Rethinking Clinical Trials with Faster AI-Driven Decision Making - with Shefali Kakar of Novartis

<p><span data-preserver-spaces="true">Shefali Kakar, Global Head of PK Sciences and Oncology at Novartis, returns to the</span> <em><span data-preserver-spaces="true">AI in Business</span></em> <span data-preserver-spaces="true">podcast to discuss how AI is reshaping the earliest and most critical phases of drug development—where strategic investment decisions are made long before a clinical trial begins. Together with Emerj Editorial Director Matthew DeMello, Shefali explores how advanced modeling, in silico design, and patient data are creating a clearer picture of risk and return across R&D portfolios. She explains how pharmaceutical organizations are leveraging multi-factorial models to simulate safety, efficacy, and market potential—down to the molecular level. Want to share your AI adoption story with executive peers? Click</span> <a class="editor-rtfLink" href= "http://emerj.com/expert2" target="_blank" rel= "noopener"><span data-preserver-spaces= "true">emerj.com/expert2</span>...